Bone Health Technologies Secures $5 Million in Funding to Transform Osteopenia Care

Bone Health Technologies (BHT), a pioneer in developing non-invasive bone health solutions, has successfully raised $5 million in a new funding round. The round saw contributions from notable investment firms such as Esplanade Ventures, Berkeley Catalyst Fund, and Terumo Medical, a leading global medical technology company. Notably, representatives from Esplanade Ventures and Terumo Medical have joined BHT as board observers.

BHT is known for its Osteoboost vibration wearable, a device designed to combat bone density loss in postmenopausal women. This innovative solution not only slows the reduction of bone density but has also shown promising user adherence rates and safety profiles during clinical trials. Its upcoming market launch, expected later this year, positions Osteoboost as a significant advancement in the treatment of bone loss conditions.

The funding is a strategic move to steer BHT through the final development phases of Osteoboost, enhancing its launch readiness. The device's unique non-pharmacological approach to bone regeneration has the potential to address the widespread issue of osteopenia and osteoporosis, affecting over 64 million people in the U.S. alone.

Laura Yecies, CEO of BHT, emphasized the rigorous validation process that Osteoboost underwent to ensure reliability for users and physicians. The recent FDA clearance of Osteoboost marks a crucial milestone towards its market introduction, signalling a new era in osteopenia care.